Skip to main content
SpringerLink
Log in

Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy

  • Letter to the Editor
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bronnimann C, Izquierdo C, Cartalat S, Thomas L, Joubert B, Delpech L, Barritault M, Meyronet D, Honnorat J, Ducray F (2018) Rechallenge with bevacizumab in patients with glioblastoma progressing off therapy. J Neuro-Oncol. https://doi.org/10.1007/s11060-018-2780-1

    Article  Google Scholar 

  2. Sherman WJ, Raizer JJ, Grimm SA (2013) Outcome of discontinuing bevacizumab prior to malignant glioma progression. J Neuro-Oncol 111:87–89. https://doi.org/10.1007/s11060-012-0985-2

    Article  Google Scholar 

  3. Balaña C, Estival A, Pineda E, Sepúlveda J, Mesía C, del Barco S, Gil-Gil M, Hardy M, Indacoechea A, Cardona AF (2017) Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab†. Neurooncol Pract 4:15–23. https://doi.org/10.1093/nop/npw004

    Article  Google Scholar 

Download references

Funding

This study was not funded.

Author information

Authors and Affiliations

  1. Catalan Institute of Oncology, Ctra Canyet s/n, 08916, Badalona, Spain

    Carmen Balana & Anna Estival

  2. Hospital Clinic de Barcelona, Barcelona, Spain

    Estela Pineda

Authors
  1. Carmen Balana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Estival
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Estela Pineda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carmen Balana.

Ethics declarations

Conflict of interest

Carmen Balana has received honorarium from Roche Farma S.A., AbbVie, and Celgene for advisory roles. Anna Estival declares that she has no conflict of interest. Estela Pineda declares that she has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the referred studies.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Balana, C., Estival, A. & Pineda, E. Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy. J Neurooncol 139, 779–780 (2018). https://doi.org/10.1007/s11060-018-2902-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-018-2902-9

Search

Navigation